From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers

Published on Jan 18, 2017in International Journal of Molecular Sciences4.18
· DOI :10.3390/ijms18010180
Ioannis D Kyrochristos3
Estimated H-index: 3
Georgios K. Glantzounis11
Estimated H-index: 11
+ 9 AuthorsDimitrios H Roukos62
Estimated H-index: 62
Hepatobiliary and pancreatic (HBP) cancers are associated with high cancer-related death rates. Surgery aiming for complete tumor resection (R0) remains the cornerstone of the treatment for HBP cancers. The current progress in the adjuvant treatment is quite slow, with gemcitabine chemotherapy available only for pancreatic ductal adenocarcinoma (PDA). In the advanced and metastatic setting, only two targeted drugs have been approved by the Food & Drug Administration (FDA), which are sorafenib for hepatocellular carcinoma and erlotinib for PDA. It is a pity that multiple Phase III randomized control trials testing the efficacy of targeted agents have negative results. Failure in the development of effective drugs probably reflects the poor understanding of genome-wide alterations and molecular mechanisms orchestrating therapeutic resistance and recurrence. In the post-ENCODE (Encyclopedia of DNA Elements) era, cancer is referred to as a highly heterogeneous and systemic disease of the genome. The unprecedented potential of next-generation sequencing (NGS) technologies to accurately identify genetic and genomic variations has attracted major research and clinical interest. The applications of NGS include targeted NGS with potential clinical implications, while whole-exome and whole-genome sequencing focus on the discovery of both novel cancer driver genes and therapeutic targets. These advances dictate new designs for clinical trials to validate biomarkers and drugs. This review discusses the findings of available NGS studies on HBP cancers and the limitations of genome sequencing analysis to translate genome-based biomarkers and drugs into patient care in the clinic.
  • References (176)
  • Citations (11)
#1Babs G. Sibinga Mulder (LUMC: Leiden University Medical Center)H-Index: 4
#2J. Sven D. Mieog (LUMC: Leiden University Medical Center)H-Index: 19
Last.Hans Morreau (LUMC: Leiden University Medical Center)H-Index: 51
view all 14 authors...
#1Milind Javle (University of Texas MD Anderson Cancer Center)H-Index: 28
#2Tanios Bekaii-Saab (OSU: Ohio State University)H-Index: 37
Last.J. S. Ross (Albany Medical College)H-Index: 75
view all 19 authors...
#1Catalina Mosquera (ECU: East Carolina University)H-Index: 6
#2Dino Maglic (ECU: East Carolina University)H-Index: 1
Last.Emmanuel E. Zervos (ECU: East Carolina University)H-Index: 31
view all 3 authors...
#1K Schulze (UHH: University of Hamburg)H-Index: 8
#2Jean-Charles Nault (French Institute of Health and Medical Research)H-Index: 20
Last.Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 45
view all 3 authors...
#1Yosuke HirotsuH-Index: 9
#2Tang-Hui Zheng (Ha Tai: Xiamen University)H-Index: 1
Last.Masao Omata (UTokyo: University of Tokyo)H-Index: 121
view all 6 authors...
#1Olca Basturk (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 34
#2Marcus C.B. Tan (USA: University of South Alabama)H-Index: 14
Last.David S. Klimstra (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 109
view all 15 authors...
Cited By11
#1Vivian Weiwen Xue (PolyU: Hong Kong Polytechnic University)H-Index: 3
#2Cesar Sze Chuen Wong (PolyU: Hong Kong Polytechnic University)H-Index: 1
Last.William C. S. ChoH-Index: 11
view all 3 authors...
#1Liming Wu (ZJU: Zhejiang University)H-Index: 16
#2Le-Le Zhang (ZJU: Zhejiang University)H-Index: 1
Last.Shusen Zheng (ZJU: Zhejiang University)H-Index: 42
view all 4 authors...
#1Jeffery Ho (CUHK: The Chinese University of Hong Kong)H-Index: 6
#2Xianchun Li (CUHK: The Chinese University of Hong Kong)H-Index: 1
Last.William K.K. Wu (CUHK: The Chinese University of Hong Kong)H-Index: 47
view all 11 authors...
#1Georgios K. Glantzounis (UoI: University of Ioannina)H-Index: 11
#2A. Paliouras (UoI: University of Ioannina)H-Index: 1
Last.Evangelos Felekouras (UoA: National and Kapodistrian University of Athens)H-Index: 20
view all 8 authors...
View next paperMutation Profiling of Clinically Advanced Cancers Using Next-Generation Sequencing for Targeted Therapy: A Lifespan Experience